Results 81 to 90 of about 405 (90)

TAC1b mutation in Candida auris decreases manogepix susceptibility owing to increased CDR1 expression. [PDF]

open access: yesAntimicrobial Agents and Chemotherapy
Candida auris is an emerging pathogenic fungus that is highly resistant to existing antifungal drugs. Manogepix is a novel antifungal agent that exerts antifungal activity by inhibiting glycosylphosphatidylinositol anchor biosynthesis.
Masato Tashiro   +2 more
exaly   +4 more sources
Some of the next articles are maybe not open access.

Related searches:

Activities of Manogepix and Comparators against 1,435 Recent Fungal Isolates Collected during an International Surveillance Program (2020).

Antimicrobial Agents and Chemotherapy, 2022
Michael D Huband   +2 more
exaly  

Enhanced Efflux Pump Expression in Candida Mutants Results in Decreased Manogepix Susceptibility.

Antimicrobial Agents and Chemotherapy, 2020
Leah E Cowen   +2 more
exaly  

In Vitro Activity of Manogepix against Multidrug-Resistant and Panresistant Candida auris from the New York Outbreak.

Antimicrobial Agents and Chemotherapy, 2020
Vishnu Chaturvedi   +2 more
exaly  

Synthesis of analogs of the Gwt1 inhibitor manogepix (APX001A) and evaluation against spp

Bioorganic and Medicinal Chemistry Letters, 2019
Karen J Shaw, Mili Kapoor
exaly  

Evaluation of Resistance Development to the Gwt1 Inhibitor Manogepix (APX001A) in Candida Species.

Antimicrobial Agents and Chemotherapy, 2019
Karen J Shaw, Mili Kapoor
exaly  

Home - About - Disclaimer - Privacy